Access the full text.
Sign up today, get DeepDyve free for 14 days.
EC Somoza, D Winship, CW Gorodetzky (2013)
A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence [published online April 10, 2013]., 70
S. Comer, M. Sullivan, E. Yu, J. Rothenberg, H. Kleber, K. Kampman, C. Dackis, C. O'brien (2006)
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.Archives of general psychiatry, 63 2
E. Krupitsky, E. Nunes, W. Ling, A. Illeperuma, D. Gastfriend, B. Silverman (2011)
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trialThe Lancet, 377
E. Somoza, D. Winship, C. Gorodetzky, D. Lewis, D. Ciraulo, G. Galloway, S. Segal, Michael Sheehan, J. Roache, W. Bickel, D. Jasinski, D. Watson, S. Miller, Peggy Somoza, T. Winhusen (2013)
A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.JAMA psychiatry, 70 6
J. Brodie, B. Case, Emilia Figueroa, S. Dewey, James Robinson, J. Wanderling, E. Laska (2009)
Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees.The American journal of psychiatry, 166 11
S. Hopewell, Kirsty Loudon, M. Clarke, A. Oxman, K. Dickersin (2009)
Publication bias in clinical trials due to statistical significance or direction of trial results.The Cochrane database of systematic reviews, 1
News and events.
EDITORIAL An Illustrative Example LINICAL TRIALS WITH POSITIVE FINDINGS In the prior study, 28.0% of participants in the vigaba- are more likely to be submitted and pub- trin group and 7.5% of the participants in the placebo lished than those with negative find- groups met the criteria for end-of-trial abstinence, a dif- ings, but negative findings can provide ference that could have been affected substantially by the C invaluable information, particularly when differential rates of retention in the 2 groups. This meth- based on sound methodology. The study by Somoza and odological limitation makes it difficult to determine colleagues in this issue provides a powerful illustration whether vigabatrin directly reduced cocaine use or of the potential value of a negative finding. whether it just affected retention in treatment. This is not to say that one study is correct and the other is incor- rect. Indeed, Somoza et al reported an effect on semi- See also page 630 quantitative benzoylecognine urinalysis results, which Somoza et al report the results of a clinical trial that provides some suggestion that vigabatrin may have af- evaluated the safety and efficacy of vigabatrin for treating fected cocaine use. However, the lack of an effect
JAMA Psychiatry – American Medical Association
Published: Jun 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.